Phaseline

Targets › ADORA2B

ADORA2B (Adenosine receptor A2b): drug programs, companies and trials

32 programs from 32 companies in 50 trials: 22 Phase 2, 13 Phase 4, 8 Phase 1, 7 Phase 3; Other, Cardiovascular, Oncology; next expected readout Dec 2026.

Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. (UniProt, P29275)

Open in Phaseline: the race on ADORA2B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
St Joseph University, Beirut, LebanonPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 4Lumbar RadiculopathyDec 2026
Region SkaneAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Chronic Coronary SyndromeDec 2026
National Institute of Cardiovascular Diseases, PakistanAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4ST-Segment Elevation Myocardial Infarction (STEMI)Dec 2026
University of Alabama at BirminghamCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Premature Infant DiseaseMay 2027
Anne E. Zepeskiadenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Supraventricular Tachycardia (SVT)Jul 2027
Semmelweis UniversityCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Apnea of PrematurityDec 2027
Weill Medical College of Cornell UniversityAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Premature Ventricular Contraction (PVC)Dec 2027
VA Office of Research and DevelopmentPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 4Diabetic Kidney DiseaseJan 2028
Vastra Gotaland RegionAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Takotsubo SyndromeDec 2028
RDC ClinicalCaffeine
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 4Exercise; Migraine; Healthy; Vibration Therapy …–
Al-Azhar UniversityPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Chronic Kidney DiseasesDec 2026
Tanta UniversityPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3IBS - Irritable Bowel Syndrome; Rheumatoid ArthritisMay 2027
NICHD Global Network for Women's and Children's HealthCaffeine Citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 3Hypoxic Ischemic Encephalopathy (HIE)Dec 2029
Rashid Latif Medical CollegeAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 3Supraventricular Tachycardia (SVtach)–
University of WashingtonPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Medication-related Osteonecrosis of the Jaw–
Beni-Suef Universitypentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 3Embryo Transfer–
New York Medical CollegeDefibrotide
Adenosine A2 receptor agonist; Plasminogen activator; Adenosine A1 receptor agonist
ADORA2B, ADORA2A, PLG, ADORA1, F2Phase 2Sickle Cell Disease; Sinusoidal Obstruction SyndromeDec 2026
Mostafa BahaaPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2EpilepsyDec 2026
Ihab Elsayed HassanPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Inflammatory Bowel DiseasesJan 2027
University Hospital, LimogesPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Medication-related Osteonecrosis of the Jaw (MRONJ)Apr 2027
Ministry of Health, Saudi ArabiaCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 2PrematurityOct 2027
University of RochesterCaffeine Citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 2Neonatal ApneaJul 2028
M.D. Anderson Cancer CenterPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Lymphedema; Fibrosis SyndromeMay 2029
Gilead SciencesEtrumadenant
Adenosine A2a receptor antagonist; Adenosine A2b receptor antagonist
ADORA2A, ADORA2BPhase 2Lung Cancer; Oligometastatic Prostate Cancer; Rectal Cancer; Pancreatic Ductal Adenocarcinoma …Sep 2029
University of Wisconsin, MadisonCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 2Kidney InjuryMar 2030
University Health Network, TorontoPentoxifylline
Adenosine A2 receptor antagonist; 3',5'-cyclic phosphodiesterase inhibitor
ADORA2B, ADORA2A, PDE5A, PDE4A, PDE3APhase 2Non-Small Cell Lung CancerNov 2031
Dwight OwenPBF-1129
Adenosine A2B receptor antagonist
ADORA2BPhase 1Metastatic Lung Non-Small Cell CarcinomaDec 2026
Indiana UniversityCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Preterm Labor With Preterm DeliveryJun 2027
University of ChicagoCaffeine citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Enhanced Recovery After Surgery in a Pediatric PopulationDec 2027
University of North Carolina, Chapel HillCaffeine Citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Hypoxic-Ischemic EncephalopathyJul 2028
McMaster UniversityAdenosine
Adenosine receptor agonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Chronic Cough (CC)–
Nishtar Medical UniversityCaffeine Citrate
Adenosine receptor antagonist
ADORA1, ADORA2B, ADORA3, ADORA2APhase 1Apnea of Prematurity–

Conditions

Apnea of Prematurity (3) Hypoxic-Ischemic Encephalopathy (2) Supraventricular Tachycardia (SVT) (1) Medication-related Osteonecrosis of the Jaw (1) Medication-related Osteonecrosis of the Jaw (MRONJ) (1) Premature Infant Disease (1) Sickle Cell Disease (1) Sinusoidal Obstruction Syndrome (1) Lung Cancer (1) Oligometastatic Prostate Cancer (1) Rectal Cancer (1) Pancreatic Ductal Adenocarcinoma (1)

Modalities

small molecule (28), mixed (2), protein or peptide (1)

Companies

Anne E. Zepeski (1) University of Washington (1) University Hospital, Limoges (1) Semmelweis University (1) University of Alabama at Birmingham (1) New York Medical College (1) Gilead Sciences (1) RDC Clinical (1) Mostafa Bahaa (1) M.D. Anderson Cancer Center (1) Weill Medical College of Cornell University (1) Vastra Gotaland Region (1) University of Chicago (1) Dwight Owen (1) McMaster University (1) VA Office of Research and Development (1) Region Skane (1) Ihab Elsayed Hassan (1) Indiana University (1) Ministry of Health, Saudi Arabia (1)

Related targets

ADORA2A (31) ADORA1 (19) ADORA3 (18) PDE5A (11) PDE4A (11) PDE3A (11) PLG (1) F2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.